512 related articles for article (PubMed ID: 34905388)
1. Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Lyu N; Wang X; Li JB; Lai JF; Chen QF; Li SL; Deng HJ; He M; Mu LW; Zhao M
J Clin Oncol; 2022 Feb; 40(5):468-480. PubMed ID: 34905388
[TBL] [Abstract][Full Text] [Related]
2. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial.
Li QJ; He MK; Chen HW; Fang WQ; Zhou YM; Xu L; Wei W; Zhang YJ; Guo Y; Guo RP; Chen MS; Shi M
J Clin Oncol; 2022 Jan; 40(2):150-160. PubMed ID: 34648352
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
He M; Li Q; Zou R; Shen J; Fang W; Tan G; Zhou Y; Wu X; Xu L; Wei W; Le Y; Zhou Z; Zhao M; Guo Y; Guo R; Chen M; Shi M
JAMA Oncol; 2019 Jul; 5(7):953-960. PubMed ID: 31070690
[TBL] [Abstract][Full Text] [Related]
4. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Choi JH; Chung WJ; Bae SH; Song DS; Song MJ; Kim YS; Yim HJ; Jung YK; Suh SJ; Park JY; Kim DY; Kim SU; Cho SB
Cancer Chemother Pharmacol; 2018 Sep; 82(3):469-478. PubMed ID: 29982870
[TBL] [Abstract][Full Text] [Related]
5. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Lyu N; Kong Y; Mu L; Lin Y; Li J; Liu Y; Zhang Z; Zheng L; Deng H; Li S; Xie Q; Guo R; Shi M; Xu L; Cai X; Wu P; Zhao M
J Hepatol; 2018 Jul; 69(1):60-69. PubMed ID: 29471013
[TBL] [Abstract][Full Text] [Related]
6. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial.
Kondo M; Morimoto M; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Aikata H; Hatanaka T; Takizawa D; Matsunaga K; Okuse C; Suzuki M; Taguri M; Ishibashi T; Numata K; Maeda S; Tanaka K
BMC Cancer; 2019 Oct; 19(1):954. PubMed ID: 31615466
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
Kudo M; Ueshima K; Yokosuka O; Ogasawara S; Obi S; Izumi N; Aikata H; Nagano H; Hatano E; Sasaki Y; Hino K; Kumada T; Yamamoto K; Imai Y; Iwadou S; Ogawa C; Okusaka T; Kanai F; Akazawa K; Yoshimura KI; Johnson P; Arai Y;
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):424-432. PubMed ID: 29631810
[TBL] [Abstract][Full Text] [Related]
8. Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis.
Liu M; Shi J; Mou T; Wang Y; Wu Z; Shen A
J Gastroenterol Hepatol; 2020 Aug; 35(8):1277-1287. PubMed ID: 32052876
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial.
Zheng K; Zhu X; Fu S; Cao G; Li WQ; Xu L; Chen H; Wu D; Yang R; Wang K; Liu W; Wang H; Bao Q; Liu M; Hao C; Shen L; Xing B; Wang X
Radiology; 2022 May; 303(2):455-464. PubMed ID: 35103539
[TBL] [Abstract][Full Text] [Related]
10. Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis.
Hu J; Bao Q; Cao G; Zhu X; Yang R; Ji X; Xu L; Zheng K; Li W; Xing B; Wang X
Cardiovasc Intervent Radiol; 2020 Jul; 43(7):996-1005. PubMed ID: 31974744
[TBL] [Abstract][Full Text] [Related]
11. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin in Hepatocellular Cancer with Extrahepatic Spread.
Lyu N; Kong Y; Pan T; Mu L; Li S; Liu Y; Deng H; Li J; Shi M; Xu L; Guo R; Chen M; Wu P; Zhao M
J Vasc Interv Radiol; 2019 Mar; 30(3):349-357.e2. PubMed ID: 30819477
[TBL] [Abstract][Full Text] [Related]
12. A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Song DS; Song MJ; Bae SH; Chung WJ; Jang JY; Kim YS; Lee SH; Park JY; Yim HJ; Cho SB; Park SY; Yang JM
J Gastroenterol; 2015 Apr; 50(4):445-54. PubMed ID: 25027973
[TBL] [Abstract][Full Text] [Related]
13. Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis.
He MK; Zou RH; Li QJ; Zhou ZG; Shen JX; Zhang YF; Yu ZS; Xu L; Shi M
Cardiovasc Intervent Radiol; 2018 May; 41(5):734-743. PubMed ID: 29327075
[TBL] [Abstract][Full Text] [Related]
14. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
Kawaoka T; Aikata H; Hyogo H; Morio R; Morio K; Hatooka M; Fukuhara T; Kobayashi T; Naeshiro N; Miyaki D; Hiramatsu A; Imamura M; Kawakami Y; Takahashi S; Waki K; Tsuji K; Kohno H; Kohno H; Moriya T; Chayama K
J Dig Dis; 2015 Sep; 16(9):505-12. PubMed ID: 26121102
[TBL] [Abstract][Full Text] [Related]
15. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Sorafenib for Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization: Retrospective Subgroup Analysis of 2 Prospective Trials.
Huang Y; Zhang L; He M; Lai Z; Bu X; Wen D; Li Q; Xu L; Wei W; Zhang Y; Zhou Z; Chen M; Guo R; Shi M; Kan A
Technol Cancer Res Treat; 2022; 21():15330338221117389. PubMed ID: 36529949
[No Abstract] [Full Text] [Related]
16. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis.
Kodama K; Kawaoka T; Aikata H; Uchikawa S; Nishida Y; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Kimura T; Nagata Y; Chayama K
Oncology; 2018; 94(4):215-222. PubMed ID: 29428943
[TBL] [Abstract][Full Text] [Related]
17. Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma.
Han S; Choi HJ; Beom SH; Kim HR; Lee H; Lee JS; Lee HW; Park JY; Kim SU; Kim DY; Ahn SH; Han KH; Seong J; Won JY; Kim BK
J Cancer Res Clin Oncol; 2021 Oct; 147(10):3123-3133. PubMed ID: 33893539
[TBL] [Abstract][Full Text] [Related]
18. Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial.
Hatooka M; Kawaoka T; Aikata H; Inagaki Y; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Awai K; Masaki K; Waki K; Kohno H; Kohno H; Moriya T; Nagaoki Y; Tamura T; Amano H; Katamura Y; Chayama K
BMC Cancer; 2018 Jun; 18(1):633. PubMed ID: 29866075
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.
Chen S; Xu B; Wu Z; Wang P; Yu W; Liu Z; Huang X; Wu Y; Li T; Guo W
BMC Cancer; 2021 Oct; 21(1):1126. PubMed ID: 34670506
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a comparative study using the propensity score matching method.
Fukubayashi K; Tanaka M; Izumi K; Watanabe T; Fujie S; Kawasaki T; Yoshimaru Y; Tateyama M; Setoyama H; Naoe H; Kikuchi K; Sasaki Y
Cancer Med; 2015 Aug; 4(8):1214-23. PubMed ID: 26044168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]